Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities  Fasiha Kanwal, Donna L. White, Shahriar Tavakoli–Tabasi, Li Jiao, Derek Lin, David J. Ramsey, Andrew Spiegelman, Jill Kuzniarek, Hashem B. El–Serag  Clinical Gastroenterology and Hepatology  Volume 12, Issue 2, Pages 327-333.e1 (February 2014) DOI: 10.1016/j.cgh.2013.08.034 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 Distribution of IL28B genotype (rs12980275) by treatment eligibility. Segments 1 and 2 represent subgroups of patients considered ineligible for antiviral treatment. Of these, approximately 40% had a favorable IL28B genotype (segment 1). One fourth of the patients had a favorable genotype and also was eligible for treatment (segment 3). However, a significant proportion of patients without any major treatment exclusion had an unfavorable IL28B genotype (segment 4). Clinical Gastroenterology and Hepatology 2014 12, 327-333.e1DOI: (10.1016/j.cgh.2013.08.034) Copyright © 2014 AGA Institute Terms and Conditions